Limited Competition for the Continuation of the Consortium for Radiologic Imaging

放射成像联盟延续的有限竞争

• 批准号: 9044528
• 负责人: ARLENE B CHAPMAN
• 金额: $ 33.15万
• 依托单位: UNIVERSITY OF CHICAGO
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-06-01 至 2017-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9044528
• 关键词: Address; Affect; Age; Alabama; Ancillary Study; Autosomal Dominant Polycystic Kidney; Biological; Biological Markers; Characteristics; Clinic; Clinical; Clinical Data; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Counseling; Cyst; Cystic kidney; DNA; Data; Data Analyses; Development; Diet; Disease Progression; End stage renal failure; Family member; Funding; Genetic; Genetic study; Genotype; Goals; Growth; Hepatic Cyst; Image; Individual; Intake; Intervention; Kansas; Kidney; Kidney Diseases; Kidney Failure; Life Expectancy; Liver; Magnetic Resonance; Magnetic Resonance Imaging; Measurement; Methods; Modeling; Morbidity - disease rate; National Institute of Diabetes and Digestive and Kidney Diseases; Nature; Other Genetics; Participant; Patient Outcomes Assessments; Patients; Pattern; Phenotype; Pilot Projects; Polycystic Kidney Diseases; Population; Predictive Value; Principal Investigator; Proteomics; Quality of life; Renal Blood Flow; Research Personnel; Resources; Risk; Risk Factors; Role; Sampling; Sensitivity and Specificity; Severities; Severity of illness; Sodium; Surrogate Markers; Testing; Universities; Washington; base; drug development; follow-up; genetic risk factor; improved; modifiable risk; predictive marker; programs; repository; serological marker; sex; urinary

DESCRIPTION (provided by applicant): Autosomal dominant polycystic kidney disease (ADPKD) is a major cause of morbidity and is the fourth leading cause of ESRD in the world, affecting more than 500,000 U.S. citizens. Researchers at the University of Alabama, Emory University, University of Kansas, Mayo Clinic and Washington University joined together in 2000 to create the Consortium for Radiologic Studies of Polycystic Kidney Disease (CRISPI) and in 2006 included the University of Pittsburgh in place of Washington University for CRISP II. The primary objectives of CRISPI and II were to: establish accurate, reliable and reproducible magnetic resonance based measurements of total kidney volume (TKV), liver cyst volume (LCV), renal blood flow (RBF), and patterns of cyst growth and expansion. Based on 7.3 years of longitudinal followup in 200 CRISP l/ll participants, we can now 1) establish an uniquivocal relationship between TKV and qualitative (patient reported outcomes) and quantitative (renal insufficiency) end-points; as well as 2) identify potential modifiable risk factors associating with TKV and LCV to intervene upon. TKV ultimately may be used as a surrogate marker of disease progression in clinical trials. The goals of CRISPIN extend the observations of CRISPI/II. The overarching Aim for CRISP III is to develop and enhance prediction models that best predict renal insufficiency in ADPKD. Specifically, Aim 1: Extend the serial quantification of TKV and LCV to develop and test new models for predicting the risk of developing renal insufficiency. Aim 2: Determine the extent to which age and sex-adjusted measurements of RBF predict the rate of change in TKV and determine if RBF and TKV independently predict the risk of developing renal insufficiency. Aim 3: Develop methods to quantify the influence of renal cyst number, volume, and topography at baseline on the subsequent course of TKV and GFR and the risk of developing renal insufficiency. Aim 4: Expand and analyze CRISP biological samples to improve genotype/phenotype and biomarker studies. Aim 5. Determine whether intensive dietary counseling and intervention in a small group of CRISP participants is successful in modifying the relatively fixed pattern of sodium intake observed in CRISPI and reducing the rate of growth of the polycystic kidneys.

描述（由申请人提供）：常染色体显性多囊肾病 (ADPKD) 是发病的主要原因，也是世界上 ESRD 的第四大原因，影响超过 500,000 名美国公民。阿拉巴马大学、埃默里大学、堪萨斯大学、梅奥诊所和华盛顿大学的研究人员于 2000 年联合创建了多囊肾病放射学研究联盟 (CRISPI)，并于 2006 年将匹兹堡大学纳入其中以取代华盛顿大学对于 CRISP II。 CRISPI 和 II 的主要目标是：建立基于磁共振的准确、可靠和可重复的肾总体积 (TKV)、肝囊肿体积 (LCV)、肾血流量 (RBF) 以及囊肿生长和扩张模式的测量。基于 200 名 CRISP l/ll 参与者 7.3 年的纵向随访，我们现在可以 1) 建立 TKV 与定性（患者报告的结果）和定量（肾功能不全）终点之间的明确关系； 2) 确定与 TKV 和 LCV 相关的潜在可改变风险因素以进行干预。 TKV 最终可能在临床试验中用作疾病进展的替代标志物。 CRISPIN 的目标扩展了 CRISPI/II 的观察结果。 CRISP III 的总体目标是开发和增强最能预测 ADPKD 肾功能不全的预测模型。具体来说，目标 1：扩展 TKV 和 LCV 的连续量化，以开发和测试预测肾功能不全风险的新模型。目标 2：确定年龄和性别调整后的 RBF 测量值预测 TKV 变化率的程度，并确定 RBF 和 TKV 是否独立预测发生肾功能不全的风险。目标 3：开发方法来量化基线时肾囊肿数量、体积和地形对后续 TKV 和 GFR 进程以及发生肾功能不全风险的影响。目标 4：扩展和分析 CRISP 生物样本，以改进基因型/表型和生物标志物研究。目标 5. 确定对一小群 CRISP 参与者进行强化饮食咨询和干预是否能成功改变 CRISPI 中观察到的相对固定的钠摄入模式并降低多囊肾的生长速度。